A Multicentre, Randomised, Open-Label, Parallel-Group, Phase IIIb Study to Assess the Potential for Tezepelumab-treated Patients With Severe Asthma to Reduce Background Therapy While Sustaining Asthma Control and Clinical Remission
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide/salbutamol (Primary) ; Mannitol (Primary) ; Salbutamol (Primary) ; Tezepelumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms ARRIVAL
- Sponsors AstraZeneca
- 26 Oct 2024 Status changed from not yet recruiting to recruiting.
- 02 Jul 2024 New trial record